Cargando…
The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic
As COVID-19 cases continue to rise, it is imperative to learn more about antibodies and T-cells produced against the causative virus, SARS-CoV-2, in order to guide the rapid development of therapies and vaccines. While much of the current antibody and vaccine research focuses on the receptor-binding...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985173/ https://www.ncbi.nlm.nih.gov/pubmed/33767706 http://dx.doi.org/10.3389/fimmu.2021.637651 |
_version_ | 1783668187436417024 |
---|---|
author | Shah, Priyanka Canziani, Gabriela A. Carter, Erik P. Chaiken, Irwin |
author_facet | Shah, Priyanka Canziani, Gabriela A. Carter, Erik P. Chaiken, Irwin |
author_sort | Shah, Priyanka |
collection | PubMed |
description | As COVID-19 cases continue to rise, it is imperative to learn more about antibodies and T-cells produced against the causative virus, SARS-CoV-2, in order to guide the rapid development of therapies and vaccines. While much of the current antibody and vaccine research focuses on the receptor-binding domain of S1, a less-recognized opportunity is to harness the potential benefits of the more conserved S2 subunit. Similarities between the spike proteins of both SARS-CoV-2 and HIV-1 warrant exploring S2. Possible benefits of employing S2 in therapies and vaccines include the structural conservation of S2, extant cross-reactive neutralizing antibodies in populations (due to prior exposure to common cold coronaviruses), the steric neutralization potential of antibodies against S2, and the stronger memory B-cell and T-cell responses. More research is necessary on the effect of glycans on the accessibility and stability of S2, SARS-CoV-2 mutants that may affect infectivity, the neutralization potential of antibodies produced by memory B-cells, cross-reactive T-cell responses, antibody-dependent enhancement, and antigen competition. This perspective aims to highlight the evidence for the potential advantages of using S2 as a target of therapy or vaccine design. |
format | Online Article Text |
id | pubmed-7985173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79851732021-03-24 The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic Shah, Priyanka Canziani, Gabriela A. Carter, Erik P. Chaiken, Irwin Front Immunol Immunology As COVID-19 cases continue to rise, it is imperative to learn more about antibodies and T-cells produced against the causative virus, SARS-CoV-2, in order to guide the rapid development of therapies and vaccines. While much of the current antibody and vaccine research focuses on the receptor-binding domain of S1, a less-recognized opportunity is to harness the potential benefits of the more conserved S2 subunit. Similarities between the spike proteins of both SARS-CoV-2 and HIV-1 warrant exploring S2. Possible benefits of employing S2 in therapies and vaccines include the structural conservation of S2, extant cross-reactive neutralizing antibodies in populations (due to prior exposure to common cold coronaviruses), the steric neutralization potential of antibodies against S2, and the stronger memory B-cell and T-cell responses. More research is necessary on the effect of glycans on the accessibility and stability of S2, SARS-CoV-2 mutants that may affect infectivity, the neutralization potential of antibodies produced by memory B-cells, cross-reactive T-cell responses, antibody-dependent enhancement, and antigen competition. This perspective aims to highlight the evidence for the potential advantages of using S2 as a target of therapy or vaccine design. Frontiers Media S.A. 2021-03-09 /pmc/articles/PMC7985173/ /pubmed/33767706 http://dx.doi.org/10.3389/fimmu.2021.637651 Text en Copyright © 2021 Shah, Canziani, Carter and Chaiken. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Shah, Priyanka Canziani, Gabriela A. Carter, Erik P. Chaiken, Irwin The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic |
title | The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic |
title_full | The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic |
title_fullStr | The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic |
title_full_unstemmed | The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic |
title_short | The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic |
title_sort | case for s2: the potential benefits of the s2 subunit of the sars-cov-2 spike protein as an immunogen in fighting the covid-19 pandemic |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985173/ https://www.ncbi.nlm.nih.gov/pubmed/33767706 http://dx.doi.org/10.3389/fimmu.2021.637651 |
work_keys_str_mv | AT shahpriyanka thecasefors2thepotentialbenefitsofthes2subunitofthesarscov2spikeproteinasanimmunogeninfightingthecovid19pandemic AT canzianigabrielaa thecasefors2thepotentialbenefitsofthes2subunitofthesarscov2spikeproteinasanimmunogeninfightingthecovid19pandemic AT cartererikp thecasefors2thepotentialbenefitsofthes2subunitofthesarscov2spikeproteinasanimmunogeninfightingthecovid19pandemic AT chaikenirwin thecasefors2thepotentialbenefitsofthes2subunitofthesarscov2spikeproteinasanimmunogeninfightingthecovid19pandemic AT shahpriyanka casefors2thepotentialbenefitsofthes2subunitofthesarscov2spikeproteinasanimmunogeninfightingthecovid19pandemic AT canzianigabrielaa casefors2thepotentialbenefitsofthes2subunitofthesarscov2spikeproteinasanimmunogeninfightingthecovid19pandemic AT cartererikp casefors2thepotentialbenefitsofthes2subunitofthesarscov2spikeproteinasanimmunogeninfightingthecovid19pandemic AT chaikenirwin casefors2thepotentialbenefitsofthes2subunitofthesarscov2spikeproteinasanimmunogeninfightingthecovid19pandemic |